EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Regulatory T-cells technology and vascularized composite allotransplantation: A scoping review

Amina Oyuntogos, Pharel Njessi, Olivier Camuzard, Marion Cremoni, Antoine Sicard, Elise Lupon

Transplant Immunology · 2026

DOI: 10.1016/j.trim.2026.102417 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Transplant Immunology, 2026. Verfasst von Amina Oyuntogos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Institut Universitaire Locomoteur et du Sport, Pasteur 2 Hospital, University Côte d'Azur, Nice, Fr…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Vascularized Composite Allotransplantation, Graft Rejection. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vascularized composite allotransplantation (VCA) offers life changing reconstructive options for patients with traumatic injuries or congenital defects, restoring function and appearance. Its success is limited by strong immune responses, and long-term immunosuppression carries significant risks. Emerging cellular therapies, particularly regulatory T cells (Tregs) offer promising strategies to mitigate rejection and reduce immunosuppression dependence. Preclinical studies in animal models suggest that Treg-based approaches may improve graft survival and potentially reduce the need for conventional immunosuppression in VCA. METHODS: An all-time literature search of Regulatory T cell therapy in Vascularized Composite Allotransplantation in animal models was performed on the following electronic databases: PubMed, EMBASE, Cochrane Library, Scopus, Web of Science, and TRIP Database until August 2025. Data was analyzed for graft survival, regulatory T cell activity, chimerism, and tolerance mechanisms. RESULTS: A total of 2182 studies were screened across six databases, of which 13 met eligibility criteria and 5 were selected focusing on Treg therapy in VCA animal models. Treg therapy consistently prolonged graft survival (>200 days), promoted chimerism, reduced inflammation, and induced donor specific tolerance. CAR-Tregs demonstrated antigen-specific tolerance, while mesenchymal stem cells (MSCs) enhanced immunomodulation, particularly under hypoxic preconditioning. Other cellular therapies, including hematopoietic stem cells (HSC), also improved graft acceptance, demonstrating their potential as adjuncts or alternatives to long term immunosuppression. CONCLUSION: Cellular therapies, especially Treg based approaches such as adoptive transfer and local enrichment or induction of Tregs, consistently promote immune tolerance, suppress graft rejection, and extend allograft survival in VCA animal models. These approaches reduce the need for long term immunosuppression and create a pro-tolerogenic environment, supporting their translational potential. However, further clinical validation is required to optimize dosing, persistence and safety for application in human VCA recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryVascularized Composite AllotransplantationGraft RejectionAnimalsHumansGraft SurvivalTransplantation ToleranceImmune ToleranceImmunosuppression Therapy

Stichwörter der Autor:innen

Cellular therapyChimerismImmune toleranceRegulatory T cells (Tregs)Vascularized composite allotransplantation

Autor:innen und Institutionen

  • Department of Plastic and Reconstructive Surgery, Institut Universitaire Locomoteur et du Sport, Pasteur 2 Hospital, University Côte d'Azur, Nice, France; Université Côte d'Azur, CNRS, LP2M, France. Electronic address:…
  • Department of Plastic and Reconstructive Surgery, Institut Universitaire Locomoteur et du Sport, Pasteur 2 Hospital, University Côte d'Azur, Nice, France; Université Côte d'Azur, CNRS, LP2M, France.
  • Department of Plastic and Reconstructive Surgery, Institut Universitaire Locomoteur et du Sport, Pasteur 2 Hospital, University Côte d'Azur, Nice, France. Electronic address: camuzard.o@chu-nice.fr.
  • Université Côte d'Azur, CNRS, IRCAN, France; Department of Nephrology, Dialysis and Kidney Transplantation, University Hospital of Nice, Nice, France; Immunology Laboratory, University Hospital of Nice, Nice, France. El…
  • Université Côte d'Azur, CNRS, LP2M, France; Department of Nephrology, Dialysis and Kidney Transplantation, University Hospital of Nice, Nice, France. Electronic address: sicard.a@chu-nice.fr.

Zitieren

APA

Oyuntogos, A., Njessi, P., Camuzard, O., Cremoni, M., Sicard, A., & Lupon, E. (2026). Regulatory T-cells technology and vascularized composite allotransplantation: A scoping review. Transplant Immunology. https://doi.org/10.1016/j.trim.2026.102417

Vancouver

Oyuntogos A, Njessi P, Camuzard O, Cremoni M, Sicard A, Lupon E. Regulatory T-cells technology and vascularized composite allotransplantation: A scoping review. Transplant Immunology. 2026. doi:10.1016/j.trim.2026.102417

BibTeX
@article{Oyuntogos2026,
  author = {Oyuntogos, Amina and Njessi, Pharel and Camuzard, Olivier and Cremoni, Marion and Sicard, Antoine and Lupon, Elise},
  title = {Regulatory T-cells technology and vascularized composite allotransplantation: A scoping review},
  journal = {Transplant Immunology},
  year = {2026},
  doi = {10.1016/j.trim.2026.102417}
}
Kostenlos starten →